What Is an Eye Implant and How Does It Work?

An eye implant is any device surgically placed in or around the eye to restore, improve, or preserve vision. The category is surprisingly broad: it includes the tiny plastic lens a surgeon slips into your eye after cataract removal, the electrode arrays that send electrical signals to surviving retinal cells in people who have gone blind, the drainage tubes that relieve dangerous pressure in glaucoma, artificial corneas that replace a scarred or diseased front window, and even chips placed directly on the brain’s visual cortex to bypass damaged eyes altogether. Each type works by a fundamentally different mechanism, and understanding the differences matters if you or someone you know is weighing options.

The Most Common Eye Implant You Have Probably Never Thought About

By sheer numbers, the most frequently implanted eye device worldwide is the intraocular lens, or IOL. When a cataract clouds your natural lens badly enough to interfere with daily life, a surgeon removes it and replaces it with a small, clear artificial lens. The procedure is typically done under local anesthesia and takes roughly fifteen to twenty minutes per eye. Modern IOLs come in several varieties: standard single-focus lenses that give you clear distance vision (you still need reading glasses), multifocal lenses designed to reduce dependence on glasses at multiple distances, extended-depth-of-focus lenses that stretch the range of sharp vision, and toric lenses that correct astigmatism at the same time.¹ Cataract surgery with an IOL is one of the most performed operations in medicine, and for most patients the visual improvement is dramatic and long-lasting.

Because IOLs are so routine, people often do not think of them as “implants” at all. But the underlying principle is the same as with more futuristic devices: place a manufactured component inside the eye to do a job the body can no longer handle on its own. The difference is that an IOL is purely optical, bending light just as your natural lens once did, while other eye implants take on far more complex tasks.

Retinal Implants and the Bionic Eye

When people hear “eye implant,” they usually picture something closer to science fiction: a device that gives sight to someone who is completely blind. That is the goal of retinal prostheses, sometimes called bionic eyes. These devices target diseases like retinitis pigmentosa, a group of inherited conditions in which the photoreceptor cells in the retina gradually die. The key insight behind retinal implants is that even after photoreceptors are lost, a significant number of the deeper retinal cells, the bipolar and ganglion cells that relay visual signals to the brain, survive for many years.² If you can electrically stimulate those surviving cells in meaningful patterns, the brain interprets the signals as vision.

Two devices have received the most clinical attention. The Argus II, developed in the United States, sits on top of the retina (an epiretinal position). A tiny camera mounted on a pair of glasses captures images, a processor worn on the belt converts those images into electrical patterns, and the data are transmitted wirelessly to a grid of electrodes surgically attached to the retinal surface. The Alpha AMS, developed in Germany, takes a different approach: its electrode array is placed beneath the retina (subretinal position), where it sits closer to the layer the photoreceptors once occupied. Both devices have demonstrated the ability to restore basic visual function in patients with retinitis pigmentosa, allowing users to perceive light, detect motion, and recognize large objects.³

That last phrase is important to sit with: “basic visual function.” We are not talking about reading a book or recognizing a face across a room. Recipients describe seeing patterns of bright spots, called phosphenes, that correspond roughly to the shapes and movement in front of them. With training, many people learn to use these phosphene patterns to navigate a room, locate a doorway, or tell whether a person is standing nearby. The vision is crude by everyday standards, but for someone who has lived in total darkness, it can be transformative.

Why the Resolution Is Still Low

A healthy human retina contains well over 100 million photoreceptors. Current retinal implants have electrode arrays with, at most, a few hundred electrodes. Each electrode generates roughly one phosphene, so the resulting image is something like a very low-resolution grid of light dots. Researchers have been working to shrink electrode sizes and pack more of them into the array, but there are physical limits. Studies on subretinal devices have found that electrode pixels smaller than about 55 micrometers run into problems with electrical crosstalk, where the current from one pixel bleeds into its neighbors and blurs the image rather than sharpening it.⁴

Getting around this bottleneck is one of the field’s central challenges. Simply adding more electrodes does not help if their signals interfere with each other. Researchers are exploring new electrode materials and array geometries to push the resolution higher, but for now, the gap between what a bionic eye delivers and what a healthy eye provides remains enormous.

When Retinal Implants Cannot Help

Retinal implants rely on intact wiring from the retina to the brain. If the optic nerve is severely damaged or the retina itself has been destroyed by trauma or disease beyond the photoreceptor layer, there is nothing left for the electrodes to stimulate. This is where cortical visual prostheses come in. These devices bypass the eye and the optic nerve entirely, placing electrodes directly on or in the visual cortex at the back of the brain. Electrical stimulation of cortical neurons produces phosphenes just as retinal stimulation does, but without depending on any part of the eye being functional.⁵

Cortical prostheses are far less mature than retinal ones. The surgery is more invasive since it involves opening the skull, and mapping the visual cortex precisely enough to produce a coherent image is a formidable problem. Early experiments confirmed decades ago that direct cortical stimulation could elicit phosphenes, but translating those flashes into usable vision for daily tasks remains an active area of research. If it succeeds, a cortical prosthesis could serve patients for whom no other visual implant is an option, including those blinded by severe eye trauma or optic nerve damage.

Corneal Implants

Not every eye implant involves electronics. The cornea, the clear dome at the front of the eye, can become opaque from scarring, infection, chemical burns, or genetic disease. When a donor cornea transplant is not feasible or has failed repeatedly, an artificial cornea, also called a keratoprosthesis, may be the last route to restoring sight. The KeraKlear, for example, is an artificial cornea made from a biocompatible polymer. In patients with severely compromised eyes, including some with aniridia (absence of the iris), implantation of the KeraKlear has led to significant improvements in visual acuity.⁶

Newer designs aim to mimic the mechanical and optical properties of the natural cornea even more closely. A recent prototype artificial cornea achieved light transmission between 92% and 96% across the visible spectrum, close to what a healthy cornea provides, and matched the native cornea’s flexibility so it could integrate more naturally with surrounding tissue.⁷ Getting both the optics and the biocompatibility right is the central difficulty: the device must stay clear, resist infection, and avoid being rejected by the body’s immune response for years or decades.

Glaucoma Drainage Devices

Glaucoma damages the optic nerve, usually because fluid pressure inside the eye builds too high. When eye drops and laser treatments are not enough, surgeons may implant a tiny drainage device to create a new outflow path for fluid. The Ahmed Glaucoma Valve is one of the most widely used. Despite its name, it functions more as a flow-restriction device than a true valve that opens and closes in direct response to pressure changes.⁸ A small silicone tube inserted into the front chamber of the eye channels excess fluid to a plate positioned on the outer surface of the eyeball, where it is absorbed by surrounding tissue. The goal is to keep pressure within a safe range, preserving whatever vision remains rather than restoring vision that has already been lost. Glaucoma drainage implants do not reverse nerve damage; they prevent more of it.

What Everyday Life Looks Like After a Retinal Implant

Because bionic-eye technology attracts so much media attention, expectations can run well ahead of reality. A systematic review of retinal-implant outcomes found that quality of life improved in specific practical domains, particularly mobility, orientation, and daily living tasks.⁹ One study using the Argus II found that the implant significantly improved patients’ sense of independence and their ability to carry out daily roles, though overall quality-of-life utility scores did not change dramatically from pre-implant levels. Another study reported that roughly 70% of participants rated the implant’s effect as positive or mildly positive at both one and two years after surgery, with the proportion describing the experience as clearly positive rising from about 41% at one year to 53% at two years.⁹

No participant in these studies reported a negative effect on quality of life from the implant. That is reassuring, but the picture is nuanced: improved mobility and orientation are meaningful gains, while tasks requiring fine detail, like reading print, remain largely out of reach with current devices. This gap between what helps you move through a room and what helps you read a sign is a recurring theme in the field.

Research on simulated binocular (two-eye) retinal implants adds another dimension. When volunteers experienced simulated bionic vision through two implants rather than one, they performed better on spatial perception and mobility tasks, likely because the wider field of view and rudimentary depth cues helped with hand-eye coordination and navigation. However, the two-implant setup did not outperform a single implant for recognizing static patterns or fine details.¹⁰ In other words, two bionic eyes help you walk through a crowd better, but they do not yet help you see the crowd’s faces.

Risks and Complications

Any surgery carries risk, and implanting a device inside the eye adds the possibility of long-term complications that purely biological tissue does not face. One recurring issue is fibrotic encapsulation: the body treats the implant as a foreign object and wraps it in scar tissue. In one documented case involving a drug-releasing implant in the back of the eye, a fibrotic membrane developed around the device within six weeks, eventually contributing to a recurrent retinal detachment.¹¹ In another set of cases involving a different implant type, fibrotic capsules that formed around the device were surgically removed and normal implant function was restored, suggesting the problem is manageable but needs monitoring.¹²

For electronic retinal implants specifically, additional concerns include infection at the implant site, erosion of the device through delicate ocular tissue over time, migration of the electrode array away from its intended position, and the long-term stability of the electronics inside the warm, wet environment of the eye. Improving the biocompatibility of implant materials is an ongoing focus of research to reduce these risks.³

Cost and Accessibility

Even where retinal implants have received regulatory approval, access remains limited by cost. The Argus II, when it was commercially available, carried a price tag in the range of $150,000 in the United States, and that figure did not include the surgery, hospital stay, or rehabilitation training. Regulatory approvals have been achieved for certain devices, but the reality is that high costs put bionic-eye technology out of reach for most patients globally.³ Second Sight, the company behind the Argus II, ceased operations in 2020, leaving existing recipients with devices that no longer have manufacturer support. That episode highlighted a systemic vulnerability: when your vision depends on a piece of electronics maintained by a single company, corporate failure becomes a medical problem.

For intraocular lenses and glaucoma drainage devices, the cost picture is far more favorable. Standard IOLs used in cataract surgery are covered by most public and private insurance systems worldwide, making them accessible to millions of patients each year. Premium multifocal or toric IOLs cost more out of pocket, but the base procedure itself is widely affordable. Glaucoma drainage devices are also generally covered by insurance, though their use tends to be reserved for cases where less invasive treatments have already failed.

Next-Generation Technology

The limitations of current metal-electrode retinal implants have pushed researchers toward fundamentally different materials. One especially promising direction is organic photovoltaic implants, which convert light directly into electrical current without needing external cameras, processors, or wireless power links. A fully organic retinal prosthesis tested in rats with degenerative blindness successfully restored light sensitivity, pointing toward a future generation of devices that are both highly biocompatible and functionally self-powered.¹³

At the nanoscale, researchers are building arrays from materials like graphene and carbon nanotubes that can convert incoming light into electrical pulses to stimulate retinal neurons without any wired power connection.¹⁴ One graphene-based nano-photodiode array demonstrated the ability to photovoltaically generate a current density of 245 microamps per square centimeter, enough to stimulate nearby retinal neurons.¹⁵ Computational modeling has also shown that incorporating gold nanoparticles into an organic solar cell design can triple its efficiency and activate retinal neurons at lower light levels than bare organic cells.¹⁶

These approaches are still in early stages, mostly animal models and lab benches. But the appeal is clear: a device that uses the eye’s own incoming light as its power source, without batteries or external hardware, would be simpler to implant, more comfortable to wear, and potentially far cheaper to produce.

Beyond materials, another frontier is the integration of artificial intelligence into the image-processing pipeline. Researchers have begun training neural networks to optimize how a camera image is converted into electrode stimulation patterns, essentially teaching the system to compress a complex visual scene into the small number of phosphenes the implant can produce so that the most useful information is preserved.¹⁷ If a device has only 100 or 200 phosphenes to work with, smart software that highlights edges, doorways, or faces before encoding them could make a huge practical difference.

Tear Production and the Prosthetic Eye Socket

One eye-related implant that falls outside the categories above is the ocular prosthesis, commonly called a glass eye (though modern versions are acrylic, not glass). These are cosmetic shells placed over or into an eye socket after an eye has been removed. They do not restore any vision, but they do interact with the biology of the socket in ways that matter for comfort. Research comparing tear production in prosthetic-eye wearers found that removing the cornea and inserting a prosthesis eliminates the stimulus for reflex tearing, which can leave the socket chronically dry.¹⁸ People who wear ocular prostheses often need lubricating drops to keep the socket comfortable and the prosthesis clean. It is a mundane detail compared to bionic-eye research, but for the thousands of people who wear a prosthetic eye every day, socket dryness is the implant-related problem they actually live with.

Optogenetics and Other Emerging Approaches

Electrode-based stimulation is not the only path forward for restoring sight. Optogenetics, a technique that uses gene therapy to make normally non-light-sensitive cells respond to light, is being explored as an alternative to electronic implants. The idea is to introduce light-sensitive proteins into surviving retinal ganglion cells so that they can detect light on their own, without any hardware in the eye. Early clinical trials have reported that some patients gained measurable light perception after receiving an optogenetic therapy paired with special light-amplifying goggles. Future research directions for bionic-eye technology also include fully wireless systems for power and data transmission, which could eliminate the external hardware that current devices require.³

Whether the ultimate winner in vision restoration turns out to be electronic implants, photovoltaic organic devices, optogenetic therapy, or some combination of all three is genuinely uncertain. What is clear is that each approach is suited to a different type of vision loss, a different stage of disease, and a different set of trade-offs between invasiveness, cost, and visual quality. For the foreseeable future, “eye implant” will remain a term that covers a remarkably diverse family of technologies, from a two-minute lens swap in cataract surgery to a brain electrode array that tries to paint light where none has existed for years.

1
PubMed Central. Cataract Surgery-Indications, Techniques, and Intraocular Lens Selection
2
PubMed. Towards the bionic eye–the retina implant: surgical, opthalmological and histopathological perspectives
3
PubMed Central. Can bionic eyes restore vision? Breakthroughs, challenges, and future frontiers in ophthalmology – A comprehensive review
4
PubMed Central. Electronic photoreceptors enable prosthetic visual acuity matching the natural resolution in rats
5
ScienceDirect. Cortical visual prostheses: A future paradigm shift in ophthalmology and vision restoration
6
PubMed. KeraKlear Artificial Cornea Implantation Assisted by Femtosecond Laser in Eyes With Aniridia
7
PubMed Central. Design and Biocompatibility of a Novel, Flexible Artificial Cornea
8
PubMed Central. Ahmed glaucoma valve implant: surgical technique and complications
9
PubMed Central. Do retinal implants provide long-term efficacy, safety and improve quality of life? A systematic review
10
PubMed Central. Bilateral retinal implants for improving visual restoration: a simulated bionic vision study
11
PubMed. Fibrotic encapsulation of a dexamethasone intravitreal implant following vitrectomy and silicone oil for rhegmatogenous retinal detachment
12
PubMed Central. Surgical management of fibrotic encapsulation of the fluocinolone acetonide implant in CAPN5-associated proliferative vitreoretinopathy
13
PubMed Central. A fully organic retinal prosthesis restores vision in a rat model of degenerative blindness
14
IOP Conference Series: Materials Science and Engineering. Modelling, Simulation and Analysis of NPDA for Sub-retinal implant using Nano Materials
15
Micro & Nano Letters. Design and characterisation of graphene‐based nano‐photodiode array device for photo‐stimulation of subretinal implant
16
PubMed Central. Computational analysis of efficient organic solar cell-based retinal prosthesis using plasmonic gold nanoparticles
17
PubMed Central. Towards biologically plausible phosphene simulation for the differentiable optimization of visual cortical prostheses
18
PubMed. Artificial eyes and tear measurements